1 / 46

CHARM Program: 3 Component trials comparing candesartan with placebo

This study explores the effects of candesartan versus placebo in heart failure (HF) trials, focusing on reductions in mortality and morbidity. It discusses the impact on CV death, HF hospitalization, adverse events, and more. Findings reveal positive implications for treatment outcomes and survival rates among elderly patients with preserved LV systolic function. Subgroup analyses provide valuable insights into drug discontinuations, new-onset diabetes reductions, and the combined effects of ACE inhibitors, beta-blockers, and AT1-receptor blockers.

jvandenberg
Download Presentation

CHARM Program: 3 Component trials comparing candesartan with placebo

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHARM Program: 3 Component trials comparing candesartan with placebo

  2. CHARM Program: Baseline characteristics

  3. CHARM Program: Baseline medications

  4. CHARM-Overall: CV death and non-CV death

  5. CHARM Program: Reduction in mortality and morbidity

  6. CHARM Program: Reduction in CHF hospitalization

  7. CHARM-Preserved: Hospital admissions for CHF

  8. CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis

  9. CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis (cont’d)

  10. CHARM-Added: Effect of combined ACE inhibitor/-blocker/AT1-receptor blocker

  11. CHARM-Overall: Drug discontinuations for adverse events

  12. CHARM: Clinical implications

  13. CHARM-Overall: Reduction in new-onset diabetes

  14. CHARM: Impact of treatment

  15. HF with preserved LV systolic function in the elderly: Impact on survival

  16. CHARM-Preserved: CV death or CHF hospitalization

  17. CHARM-Preserved: Primary and secondary outcomes

  18. CHARM-Preserved: Clinical implications

  19. VALIANT: Design

  20. VALIANT: Concomitant medications

  21. VALIANT: Treatments show similar effect on outcome

  22. VALIANT: Clinical implications

  23. VALIANT: Effect of treatment on mortality—Subgroup analysis

  24. RESOLVD: Comparative impact of ACE inhibitor, ARB, and -blocker alone or combined on LVEF

  25. Differences in dosing among ARB trials

  26. Survival studies of -blockade in HF

  27. -Blockers improve survival in diabetic patients with HF: A meta-analysis

  28. MERIT-HF: -Blockade improves survival in CHF

  29. MERIT-HF: -Blockade improves survival in post-MI patients with HF

  30. MERIT-HF: Subgroup analysis in post-MI patients with HF (LVEF <25%)

  31. SOLVD: Heart rate predicts progression of asymptomatic LV dysfunction

  32. MERIT-HF: Effect of -blockade on heart rate

  33. MERIT-HF: -Blockade decreases mortality and hospitalization independent of resting heart rate

  34. CHRISTMAS: Design

  35. CHRISTMAS: Trial profile

  36. CHRISTMAS: Change in LVEF according to number of segments affected by myocardial hibernation

  37. COMET: Trial profile

  38. COMET: All-cause mortality

  39. COMET: Heart rate at each visit

  40. COMET: Blood pressure

  41. -Blocker HF trials: Mortality results

  42. Mortality rates in perspective CIBIS-II, MERIT-HF, COMET

  43. Immediate-release vs sustained release metoprolol: Significant pharmacokinetic differences

  44. COMET: Clinical implications

  45. Comparison of -blocker effects in major HF trials

  46. Not all -blockers are the same

More Related